Navigation Links
Organovo Holdings, Inc. Announces Change of Fiscal Year
Date:4/3/2013

SAN DIEGO, April 3, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that the Company's Board of Directors has approved a fiscal year-end change from December 31st to March 31st, beginning on March 31, 2013.  With this change, Organovo's current fiscal year began on April 1st and will end on March 31st each year.

The change in fiscal year is in alignment with the Company's intention to apply for an initial listing on the NYSE or NASDAQ at the earliest available opportunity. 

The Company expects to file a transition report for the three-month transition period of January 1, 2013 to March 31, 2013 on Form 10-K on or about May 31, 2013.

About Organovo Holdings, Inc. 
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine and The Economist. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on March 15, 2013.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo Holdings Appoints James T. Glover to Board of Directors
2. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
3. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Organovo Reports Q2 2012 Financial Results, Provides Business Update
5. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
6. Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
7. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
8. Organovo Reports 2012 Financial Results
9. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
10. InfuSystem Holdings, Inc. To Announce First Quarter 2012 Financial Results On May 21, 2012
11. InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Research and Markets has announced ... & Forecast By Type (Insource IONM, Outsource IONM), By Region ... their offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected ... market is anticipated to witness significant growth in the forecast ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global gas chromatograph market to grow at a CAGR of ... Gas Chromatograph Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... HANOVER, N.J. , March 29, 2017 /PRNewswire/ ... Drug Administration (FDA) has accepted the company,s Biologics ... for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor ... (r/r) pediatric and young adult patients with B-cell ... BLA submission by Novartis for a CAR-T. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... In the ... to 300,000 people each year develop other types of metastatic brain tumors(3). Though most ... the brain(3). As efforts focus on finding more effective treatment options, the San ...
(Date:3/29/2017)... Massachusetts (PRWEB) , ... March 30, 2017 , ... Youth ... had great success and feedback from high school and college students who have participated ... being held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with or without a referral to new patients from Burnaby, BC. Patients in ... other full mouth reconstruction services, can see the esteemed team at Wall Centre ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... and other outpatient facilities, and who are the most active developers? , ... Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
Breaking Medicine News(10 mins):